Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Momenta and Sandoz appeal

Executive Summary

Momenta and Sandoz have filed for an interlocutory, mid-trial appeal against a US court decision that let Amphastar proceed with its antitrust case alleging the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin”.

You may also be interested in...



Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation

Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.

CIR Expert Panel Wants Nano Data For Ingredient Reviews

Are nanoparticle data necessarily relevant to every ingredient assessment undertaken by Cosmetic Ingredient Review’s independent expert panel? Let us be the judge of that, the panel said on 27 September at its 162nd meeting.

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel